Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Exanthema × capivasertib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17 Prostatic Neoplasms 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 4 Recurrence 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Leukemia 2 Healthy Participants 2 Endometrial Neoplasms 2 Disease Progression 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Non-small Cell Lung Cancer Metastatic 1 Moderate Hepatic Impairment 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1

Interventions

Gels 2 Fulvestrant 2 Doxycycline 2 Dapsone 2 ruxolitinib 1 dexpanthenol 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Sirolimus 1 Provitamins 1 Prednisone 1 Panitumumab 1 Loperamide 1 Irinotecan 1 Interviews as Topic 1 IFL protocol 1 HIV Testing 1 Fibroblast Growth Factor 7 1 Cetuximab 1 Anti-Bacterial Agents 1 Alpelisib 1 Acitretin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07426822 2026-02-24

SAFE-CAP

Yale University

Phase 2 Not yet recruiting

Diarrhea, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡